|
Reference:
1. Séchet A, Abighanem O, Said S, Rasombololona M, Morinière P, Brazier M, et al. Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis. Nephrologie. 1999;20(4):209–12.
2. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. New England Journal of Medicine. 2010;362(14):1312–24.
3. Setiani Agus L, Effendi I, Abdillah S. Influence of the use of phosphate binders on serum levels of calcium phosphate in patients with chronic kidney disease undergoing hemodialysis: A retrospective and prospective study. Saudi Pharmaceutical Journal. 2014;22(4):333–7.
4. Chan S, Au K, Francis RS, Mudge DW, Johnson DW, Pillans PI. Phosphate binders in patients with chronic kidney disease. Australian Prescriber [Internet]. 2017;40(1):10–4.
5. Calcium carbonate [Internet]. Uptodate.com. 2026. Available from: https://www.uptodate.com/contents/calcium-carbonate-drug-information.
6. Fritz K, Taylor K, Parmar M. Calcium carbonate [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562303/.
Keywords:
calcium carbonate, phosphate binder, osteoporosis
|
|